MS Matters: Managing patients through their pregnancy journey

Online webinar
16.4.2019 17:00 - 16.4.2019 18:00


Prof. Sven Schippling (Moderator): University Hospital Zürich, Switzerland

Dr Kerstin Hellwig (Co-presenter): St. Josef-Hospital/Ruhr University, Bochum, Germany

Following the success of the first CONy & Teva MS Matters live webinar, we are delighted to invite you to attend the second in the series –MS Matters: Managing patients through their pregnancy journey

Join us for an interactive discussion moderated by Prof. Sven Schippling, during which he and Dr Kerstin Hellwig will discuss issues around family planning and the management of a healthy pregnancy in women with MS. Discussion will focus on how pregnancy may have a positive, protective impact on MS via reduced disease activity as well as the weighing of potential risks of drugs damaging the foetus against risk of relapse and disability. Most disease-modifying treatments (DMTs) are not recommended during pregnancy, but can be restarted following successful delivery1. Patients should be counselled at every stage, from pregnancy planning to breast-feeding and re-starting DMTs.

There will be opportunities to ask our panel questions throughout the interactive discussion.


During the webinar we will:
  • Explore the issues around family planning and patient concerns and expectations
  • Discuss treatment decisions around when to stop DMTs for women planning to conceive
  • Consider how to counsel women of childbearing age regarding family planning and disease management



Time (CEST) Title Speaker
17:00 - 17:05 Welcome and introduction Sven Schippling
17:05 - 17:10 Family planning with MS Sven Schippling
17:10 - 17:20 Pre-pregnancy: starting out on the family planning path Kerstin Hellwig
17:20 - 17:25 Ask the audience All
17:25 - 17:35 Pregnancy: The continuing journey Sven Schippling
17:35 - 17:40 Ask the audience All
17:40 - 17:50 Post-pregnancy: Looking to the future Kerstin Hellwig
17:50 - 17:55 Ask the audience All
17:55 - 18:00 Closing remarks Sven Schippling


This webinar is organised and funded by Teva Pharmaceuticals

(Teva Pharmaceuticals Europe BV, Piet Heinkade 107, 1019 GM Amsterdam, The Netherlands)


Register here


  1. Montalban X, et al. Multiple Sclerosis Journal 2018;24:96–120.